Recent discoveries that non-small-cell lung cancer (NSCLC) can be divided into molecular 20 subtypes based on the presence or absence of driver mutations has revolutionized the treatment 21 of many patients with advanced disease. However despite these advances a majority of patients 22 are still dependent on modestly effective cytotoxic chemotherapy to provide disease control and 23 prolonged survival. In this article we review the current status of attempts to target the 24 epigenome, heritable modifications of DNA, histones and chromatin that may act to modulate 25 gene expression independently of DNA coding alterations, in NSCLC and the potential for 26 combinatorial and sequential treatment strategies. 27 28
The epigenome consists of heritable modifications of DNA, histones and chromatin that may act 48 to modulate gene expression independently of DNA coding alterations. Epigenetic changes such 49 as global DNA hypomethylation, regional DNA hypermethylation and aberrant histone 50 modification each influence the expression of oncogenes and lead to development and 51 progression of tumors(6). Crucially, epigenetic dysregulation, unlike genetic mutations, may be 52 reversed by selectively targeted therapies. Epigenetic modifications that may be readily targeted 53 with currently available therapies include regional DNA hypermethylation and histone 54 Research.
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Author Manuscript Published OnlineFirst on March 18, 2014; DOI: 10.1158 /1078 -0432.CCR-13-2088 hypoacetylation with hypomethylating agents and histone deacetylase inhibitors (HDIs) 55 respectively. 56 Tumor cells experience dramatic epigenetic changes, including CpG dinucleotide 57 hypermethylation and loss of acetylation thus downregulating tumor suppressor genes (TSGs), 58 while the converse also occurs, with pronounced hypomethylation of the promoter regions of 59 oncogenes and microsatellite regions leading to their activation (Figure 1) (7). 60 Recent data suggest that modifiable epigenetic dysregulation may also mediate a drug-resistant 61 subpopulation of cells within the heterogeneous tumor population(8).
62
To date, four drugs targeting epigenetic changes have achieved regulatory approval by the 63 United States Food and Drug Administration including decitabine, 5-azacytidine (both indicated 64 for the treatment of high risk myelodysplastic syndrome), vorinostat and romidepsin (both 65 indicated for cutaneous T cell lymphoma). While early clinical studies in NSCLC, using 66 cytotoxic doses of these drugs as single agents, showed little evidence of activity more recent 67 lower dose combination studies of HDIs and hypomethylating agents have demonstrated signals 68 of efficacy and more importantly suggest that the lung cancer epigenome can be modified in a 69 clinically relevant manner(9)(10). There are 18 human HDAC isoforms and they are divided into 4 classes (classs I-IV) with most 87 containing metalloenzymes that require Zn 2+ for catalytic activity. It is these metalloenzymes Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 18, 2014; DOI: 10.1158 /1078 -0432.CCR-13-2088 been documented in many cancers including NSCLC however several class II enzymes have also 90 been reported to be down-regulated resulting in poorer prognosis (14)(15)(16). Aberrant 91 methylation may also lead to dysregulated HDAC function in lung cancer via interactions 92 between methyl binding proteins and co-repressors such as mSin3A (17). Several studies have suggested that the presence of DNA hypermethylation in NSCLC tumor 96 cells is associated with shorter recurrence-free survival (RFS) in stage I NSCLC (18)(19).
97
In a nested case-control study of 71 stage I NSCLC patients with recurrent disease and 158 98 control stage I patients without recurrent disease, Brock et al studied methylation of six genes 99 associated with lung cancer development and growth including p16, CDH13, APC, RASSF1A,
100
MGMT, ASC and DAPK, using a multiplex methylation-specific PCR assay(18). Promoter 101 methylation of p16, CDH13, APC and RASSF1A was strongly associated with recurrence in 102 apparently curatively resected early stage patients, patients with two or more methylated genes 103 had a 5-year RFS of 27.3% compared with 65.3% for patients with fewer than two methylated 104 genes, p<0.001. Additionally methylation of both p16 and CDH13 in tumor and mediastinal 105 lymph nodes of patients was associated with a particularly poor prognosis when compared with 106 unmethylated patients (5-year RFS, 0% vs. 53.3%, p<0.001).
107
In a recent study of 587 NSCLC patients, high resolution DNA methylation analysis of CpG 108 islands was used to develop a methylation signature associated with early recurrence in resected 109 NSCLC(19). Five hypermethylated genes (HIST1H4F, PCDHGB6, NPBWR1, ALX1 and 110 HOXA9) were found to be strongly associated with reduced RFS. The gene signature developed 111 in this study divides patients into two arms, patients with zero to one methylated markers and 112 longer RFS and those with two or more methylated markers and short RFS (HR 1.95, p 0.001).
113
These findings are particularly relevant given the high rates of recurrence (30-40%) noted in disease stabilization rather than objective response being the main effect (see Table 1 ). While 145 HDI monotherapy does not appear to be a successful strategy in NSCLC there is promise that 146 when combined with demethylating agents the multi-targeting approach may have more activity. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 18, 2014; DOI: 10.1158 /1078 -0432.CCR-13-2088 Despite having previously been refractory to standard systemic therapy, 25% of patients on this 162 study had objective responses to the immediate post-study therapy (these therapies included 163 chemotherapy and also immunotherapy targeting the programmed death-1 (PD1) immune 164 checkpoint), lending support to the hypothesis that combination epigenetic therapy may modify 165 the sensitivity of tumors to systemic therapy(28).
166

Future Directions
167
With the hypothesis that epigenetic therapy may epigenetically "prime" NSCLC tumors to 168 systemic therapy, and given the interesting results noted above with standard cytotoxic therapy 169 after epigenetic therapy in previously chemo-resistant patients, we have initiated a randomized 170 phase II study for second-line advanced NSCLC (29). Patients are randomized to either standard 171 single agent chemotherapy or alternatively to initial epigenetic therapy with etinostat and oral or 172 intravenous azacytidine followed by standard single agent chemotherapy on disease progression.
173
PFS at 6 months is the primary endpoint for this study with secondary endpoints of traditional 174 PFS and overall survival (OS). We have also recently opened a randomized phase II clinical trial, 175 in the 2 nd and 3 rd line advanced NSCLC setting, examining the role of initial epigenetic therapy 176 with 5-azacytidine/etinostat or azacytidine alone for 4 cycles followed by the anti-programmed In each of these studies we will assess a panel of candidate promoter methylation markers 184 including APC, HCAD, p16, RASSF1A, GATA4 and Actin in serial plasma blood samples for 185 changes induced by epigenetic therapy and subsequent chemotherapy or immunotherapy.
186
Availability of initial tumor tissue for epigenetic analyses is a requirement for trial enrollment 187 and where possible patients will undergo repeat biopsies after epigenetic therapy. Promoter 188 methylation, gene expression analysis, driver mutational status, and other candidate markers of 189 epigenetic modulation will be evaluated in the pre-and post-treatment blood and tissue samples.
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By evaluating these markers in blood and tissue we will assess the impact of epigenetic therapy Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 18, 2014; DOI: 10.1158 /1078 -0432.CCR-13-2088 Translation of recent findings concerning the role of microRNAs and long non-coding RNAs in 198 NSCLC into clinical trials is another promising avenue of investigation though beyond the scope 199 of this article (43).
200
Conclusions 201
Epigenetic modifications play an important role in the development and progression of NSCLC.
202
Recent data on the use of gene methylation as a prognostic marker for early stage NSCLC is 203 promising and may help to direct efforts towards targeted epigenetic therapy as adjuvant therapy.
204
The potential use of epigenetic therapy as a "priming" tool prior to cytotoxic or immunologic 205 therapies for advanced NSCLC is currently being explored in prospective phase II clinical trials 206 and the results of these studies are awaited with interest. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
